Cargando…

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers

SIMPLE SUMMARY: In recent years, checkpoint inhibitor treatment of tumors has caused a stir. The response of patients with metastases showed outstanding success for some cancer types. However, many tumor types develop resistance strategies to evade this therapeutic application. This review provides...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ettl, Tobias, Grube, Matthias, Schulz, Daniela, Bauer, Richard Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599671/ https://www.ncbi.nlm.nih.gov/pubmed/36291769 http://dx.doi.org/10.3390/cancers14204985

Ejemplares similares

PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells
por: Eichberger, Jonas, et al.
Publicado: (2020)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

BMSC–HNC Interaction: Exploring Effects on Bone Integrity and Head and Neck Cancer Progression
por: Eichberger, Jonas, et al.
Publicado: (2023)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma
por: Schulz, Daniela, et al.
Publicado: (2021)

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
por: Ward, Frank J., et al.
Publicado: (2018)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Opposing MMP-9 Expression in Mesenchymal Stromal Cells and Head and Neck Tumor Cells after Direct 2D and 3D Co-Culture
por: Waltera, Anna, et al.
Publicado: (2023)

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
por: Shih, Kent, et al.
Publicado: (2014)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
por: Kim, Hyera, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors Regulate K(+) Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients
por: Gawali, Vaibhavkumar S., et al.
Publicado: (2021)

Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer
por: Chung, Chih‐Hung, et al.
Publicado: (2023)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
por: Fazer, Casey
Publicado: (2019)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
por: Matoba, Takuma, et al.
Publicado: (2022)

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
por: Pan, Cassie, et al.
Publicado: (2023)

Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients
por: van Dijk, Lisanne V., et al.
Publicado: (2016)

DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
por: Wang, Chuan, et al.
Publicado: (2021)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
por: Deneka, Alexander Y., et al.
Publicado: (2020)

Percutaneous Endoscopic Gastrostomy Tube Timing in Head and Neck Cancer Surgery
por: Din‐Lovinescu, Corina, et al.
Publicado: (2022)

Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India
por: Patil, Vijay, et al.
Publicado: (2022)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
por: Hirshoren, Nir, et al.
Publicado: (2020)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Photodynamic Therapy for Head and Neck Cancer
por: Yoshida, Tomoyuki, et al.
Publicado: (1996)

Radiation therapy in head and neck cancer
por: Alfouzan, Afnan F.
Publicado: (2021)

Speech therapy in head and neck cancer
por: Rossi, Vaneli Colombo, et al.
Publicado: (2021)

Viral and Clinical Oncology of Head and Neck Cancers
por: Goon, Peter, et al.
Publicado: (2022)

Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit
por: Johnson, Daniel E.
Publicado: (2012)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers
por: Press, Robert H., et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
por: Dong, Hui, et al.
Publicado: (2023)

Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
por: Jia, Yi-Qun, et al.
Publicado: (2019)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3anlm328i9gupqd29539eddtvt